NeuroCME
LECTURECME

Limitations of Current Therapies for RRMS

Author(s)/Faculty: Mark S. Freedman, MSc, MD, FANA, FAAN, FRCPC
Release Date: 2/21/2017Expiration Date: 2/20/2018
Credit Type: CMENumber of Credits: 0.75
Content Type: LectureProvider: Vindico Medical Education
Current disease modifying therapies (DMTs) for multiple sclerosis (MS) have been approved based on their ability to reduce relapses. Despite their impact on relapses, they have all shown variable results on slowing disease progression and reducing MRI activity. Comprehensive knowledge about DMTs is critical to ensure individualized care and treatment are provided. In this activity, expert faculty will provide a better understanding of the limitations of DMTs and how that may affect treatment for patients with MS.